Sanara MedTech, Inc. SMTI 深 滬
已收盤 05-08 16:00:00 美东时间
18.40
-0.680
-3.56%
華盛通- 最 高19.24
- 今 開19.24
- 成交量 1.77万股
- 最 低 18.09
- 昨 收 19.08
- 總市值 1.69亿
- 52周最高 35.95
- 市盈率 靜 --
- 換手率 0.19%
- 52周最低 16.0465
- 委 比 -10.71%
- 總股本 916.48万
- 歷史最高 53.85
- 量 比 0.46
- 振 幅 6.03%
- 歷史最低 16.0465
- 每 手 1
- 風險率 5.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Lake Street Initiates Coverage On Sanara MedTech with Buy Rating, Announces Price Target of $32
Lake Street analyst Frank Takkinen initiates coverage on Sanara MedTech (NASDAQ:SMTI) with a Buy rating and announces Price Target of $32.
04-15 22:18
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
Sanara MedTech Affirms FY2026 Sales Guidance of $116.000M-$121.000M
Sanara MedTech (NASDAQ:SMTI) affirms FY2026 sales outlook from $116.000 million-$121.000 million to $116.000 million-$121.000 million.
03-24 19:06
Sanara MedTech Q4 EPS $(0.13) Misses $0.11 Estimate, Sales $27.546M Beat $27.400M Estimate
Sanara MedTech (NASDAQ:SMTI) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $0.11 by 218.18 percent. This is a 230 percent decrease over earnings of $0.10 per share from the
03-24 19:03
Sanara MedTech Announces Publication Of Peer-Reviewed Study Evaluating Economic And Clinical Value Of CellerateRX Surgical Powder In Journal Of Medical Economics
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care
03-11 19:31
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
HC Wainwright & Co. Reiterates Buy on Sanara MedTech, Maintains $36 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Sanara MedTech (NASDAQ:SMTI) with a Buy and maintains $36 price target.
01-27 02:40
Sanara MedTech Expects Q4 Revenue To Be $27.2M-$27.7M, Up ~3%-5%, Compared To $26.3M In Q4 Of 2024
Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical
01-23 20:34
Sanara MedTech's BIASURGE Advanced Surgical Solution Product Receives Innovative Technology Contract From Vizient
Contract awarded for products that bring improvement to the healthcare industryFORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us")
01-08 05:09
